Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment.

被引：0
|
作者：
Kayser, Simone
Icheva, Vanya
Stevanovic, Stefan
Siebert, Nikolai
Feucht, Judith
Lode, Holger N.
Handgretinger, Rupert
Feuchtinger, Tobias
机构：
[1] Univ Childrens Hosp, Tubingen, Germany
[2] Univ Tubingen, Dept Immunol, Inst Cell Biol, Tubingen, Germany
[3] Univ Med Greifswald, Greifswald, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Univ Med Ctr, Greifswald, Germany
[5] Univ Munich, Dr von Haunersches Kinderspital, Dept Pediat Hematol Oncol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3029
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma
    Simon, T
    Hero, B
    Faldum, A
    Handgretinger, R
    Schrappe, M
    Niethammer, D
    Berthold, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (17) : 3549 - 3557
  • [32] Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO
    Siebert, Nikolai
    Zumpe, Maxi
    von Lojewski, Leon
    Troschke-Meurer, Sascha
    Marx, Madlen
    Lode, Holger N.
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [33] Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+γδT cells
    Fisher, Jonathan P. H.
    Flutter, Barry
    Wesemann, Florian
    Frosch, Jennifer
    Rossig, Claudia
    Gustafsson, Kenth
    Anderson, John
    ONCOIMMUNOLOGY, 2016, 5 (01):
  • [34] Effect of interleukin-2 on long term infusion treatment regimen of ch14.18/CHO antibody on activity in relapsed/refractory neuroblastoma patients.
    Loibner, Hans
    Siebert, Nikolai
    Eger, Christin
    Janzek, Evelyne
    Ladenstein, Ruth
    Lode, Holger N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
    Tran, Hung C.
    Wan, Zesheng
    Sheard, Michael A.
    Sun, Jianping
    Jackson, Jeremy R.
    Malvar, Jemily
    Xu, Yibing
    Wang, Larry
    Sposto, Richard
    Kim, Eugene S.
    Asgharzadeh, Shahab
    Seeger, Robert C.
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 804 - 813
  • [36] A PHASE-I STUDY OF HUMAN MOUSE CHIMERIC ANTIGANGLIOSIDE GD2 ANTIBODY CH14.18 IN PATIENTS WITH NEUROBLASTOMA
    HANDGRETINGER, R
    ANDERSON, K
    LANG, P
    DOPFER, R
    KLINGEBIEL, T
    SCHRAPPE, M
    REULAND, P
    GILLIES, SD
    REISFELD, RA
    NIETHAMMER, D
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (02) : 261 - 267
  • [37] REPORT ON LONG-TERM FOLLOW-UP OF STAGE 4 NEUROBLASTOMA
    Zhang, A.
    Tang, J. Y.
    Pan, C.
    Ye, Q. D.
    Zhou, M.
    Chen, J.
    Luo, C. Y.
    Wang, J. M.
    Tang, Y. J.
    Xue, H. L.
    Shen, S. H.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S337 - S337
  • [38] Prolactinoma with bromocriptine treatment. Long-term follow-up
    Millan-Guerrero, R. O.
    Nunez-Orozco, L.
    Escobar-Izquierdo, A.
    Isais-Millan, S.
    Ramirez-Gutierrez, R.
    REVISTA MEXICANA DE NEUROCIENCIA, 2006, 7 (06): : 581 - 585
  • [39] Follow-up in neuroblastoma:: Comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response
    Reuland, P
    Geiger, L
    Thelen, MH
    Handgretinger, R
    Haase, B
    Müller-Schauenburg, W
    Niethammer, D
    Bares, R
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2001, 23 (07) : 437 - 442
  • [40] Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-GD2 antibody therapy of stage 4 neuroblastoma
    Cheung, NKV
    Guo, HF
    Heller, G
    Cheung, IY
    CLINICAL CANCER RESEARCH, 2000, 6 (07) : 2653 - 2660
12345